The Institute of Cancer Research, London, UK.
Cancer Res. 2011 May 1;71(9):3328-40. doi: 10.1158/0008-5472.CAN-10-2734.
Telomerase is considered an attractive anticancer target on the basis of its common and specific activation in most human cancers. While direct telomerase inhibition is being explored as a therapeutic strategy, alternative strategies to target regulators of telomerase that could disrupt telomere maintenance and cancer cell proliferation are not yet available. Here, we report the findings of a high-throughput functional RNA interference screen to globally profile the contribution of kinases to telomerase activity (TA). This analysis identified a number of novel telomerase modulators, including ERK8 kinase, whose inhibition reduces TA and elicited characteristics of telomere dysfunction. Given that kinases represent attractive drug targets, we addressed the therapeutic implications of our findings, such as demonstrating how limiting TA via kinase blockade could sensitize cells to inhibition of the telomere-associated protein tankyrase. Taken together, our findings suggest novel combinatorial approaches to targeting telomere maintenance as a strategy for cancer therapy.
端粒酶因其在大多数人类癌症中的普遍和特异性激活而被认为是一种有吸引力的抗癌靶点。虽然直接抑制端粒酶作为一种治疗策略正在被探索,但靶向端粒酶调节剂的替代策略尚未出现,这些调节剂可能会破坏端粒维持和癌细胞增殖。在这里,我们报告了一项高通量功能 RNA 干扰筛选的结果,该筛选对激酶在端粒酶活性 (TA) 中的作用进行了全面分析。这项分析确定了一些新的端粒酶调节剂,包括 ERK8 激酶,其抑制作用降低了 TA,并引发了端粒功能障碍的特征。鉴于激酶是有吸引力的药物靶点,我们研究了我们发现的治疗意义,例如,证明通过激酶阻断限制 TA 如何使细胞对端粒相关蛋白 tankyrase 的抑制敏感。总之,我们的研究结果表明了针对端粒维持的新的组合方法,作为癌症治疗的一种策略。